New technologies and methods highlight 26th Annual Urology Update

Prostate cancer is currently the most commonly diagnosed cancer among Canadian men. However, according to Prostate Cancer Canada, the death rate in prostate cancer cases has been falling by an average of 3.3% per year since 2001, likely due to improved diagnosis and treatment options.

Earlier this year, a group of researchers at the University of Toronto developed a new technology for a “liquid biopsy” that could be used to identify which patients might not respond to standard prostate cancer treatment. This technology would allow for the personalization of patient treatment and would prevent healthcare professionals from providing ineffective treatment when possible. Additionally, testing patients using a blood sample is a less invasive method than that of conventional biopsies. This is one example of a new development being explored in the field.

The 26th Annual Urology Update presents an opportunity for the Urology community to stay up-to-date on current advancements and various alternatives within the field. This 2-day conference will provide participants with a deeper knowledge that will aid in the management of clinical problems. Participants will benefit from the interactive format of the conference, which will consist of lectures, audience discussions, case presentations, and debates.

Topics that will be featured include:

  • Should MRI become standard of care before prostate biopsy?
  • Should biopsy be the standard of care for small renal masses?
  • Why did Alberta and not Ontario approve robotic surgery for prostate cancer?
  • What is the best way of treating ureteral stones?
  • Do laser procedures for stress incontinence really work?
  • How effective are new office procedures for BPH?

Urology Update 2018 will take place from November 9 – 10, 2018 at the Hilton in Downtown Toronto. For more information and to register, please visit